
Biotechnology
Innovations in cancer immunotherapy: Bi-specific T cell engagers
Bi-specific T cell engagers are poised to become key immunotherapy treatments due to simpler production and new safety advances.
The case study has been sent to the email address you provided. If you did not receive it, you can download it directly by clicking the button below.
For more information, please visit CAS SciFinder Discovery Platform™.



